Search results for "COPD"

showing 10 items of 483 documents

LATE-BREAKING ABSTRACT: Phenotypes of COPD in central and Eastern Europe - The POPE study

2015

Introduction: Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries. However, data regarding symptom load and clinical phenotypes of patients with COPD in CEE remain largely unknown. Methods: Participation in the POPE Study (a multicentre, observational cross-sectional survey) was offered to consecutive outpatients with stable COPD in 11 CEE countries if they fulfilled the following criteria: age ≥ 40 years, smoking history ≥ 10 pack-years, post-bronchodilator (BD) FEV 1 /FVC Results: 3504 patients (66 ± 8.7 yrs, 69% male, post-BD FEV 1 53.0 ± 17.5% predicted, Charlson comorbidity index 2.0 ± 1.4, and 1.2 ± 1.6 exacerb…

Pediatricsmedicine.medical_specialtyCOPDeducation.field_of_studyChronic bronchitisbusiness.industryPopulationOverlap syndromemedicine.diseaserespiratory tract diseases3. Good healthEastern europeanFEV1/FVC ratioCharlson comorbidity indexmedicineObservational studybusinesseducation1.1 Clinical Problems
researchProduct

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstruct…

1998

Abstract The aims of management in mild-to-moderate stable chronic obstructive pulmonary disease (COPD) are to improve symptoms and quality of life (QOL), reduce decline in lung function, prevent and treat complications, increase survival while maintaining QOL, and minimize the adverse effects of treatment. Bronchodilator therapy is the keystone of improving COPD symptoms and functional capacity. The primary objective of this open-label study was to compare the efficacy and tolerability of salmeterol 50 μg BID administered by metered-dose inhaler versus oral, titrated, sustained-release theophylline BID, both given for 3 months to patients with a clinical history of chronic bronchitis. The …

PharmacologyCOPDChronic bronchitismedicine.drug_classbusiness.industrymedicine.diseaseTolerabilityBronchodilatorAnesthesiamedicineSalbutamolPharmacology (medical)TheophyllineSalmeterolAdverse effectbusinessmedicine.drugClinical Therapeutics
researchProduct

COPD in elderly patients – an analysis of the DACCORD observational study

2018

Introduction: In elderly patients COPD is frequently complicated by the presence of several comorbidities and the many non-COPD-related medications prescribed to treat these conditions. This analysis aims to characterize COPD patients above the age of 75 in a real-world cohort in Germany. Methods: DACCORD is a prospective, non-interventional study collecting data from COPD patients treated in primary and secondary care. Prior to study entry, patients either initiated or changed COPD maintenance medication. Moderate/severe exacerbations, COPD-medication and non-COPD medication were documented at baseline and every 3 months. Comorbidities were documented at baseline. Results: Baseline charact…

PolypharmacyCOPDmedicine.medical_specialtyExacerbationbusiness.industrymedicine.medical_treatmentmedicine.diseaserespiratory tract diseasesSecondary careInternal medicineCohortMedicineSmoking cessationIn patientObservational studybusinessClinical Problems
researchProduct

P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B

2016

Rationale The once-daily combination of tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, has demonstrated efficacy and safety in COPD. Two large clinical studies (TONADO ® 1 + 2) have also demonstrated the benefits of T/O compared to the monocomponents in patients with moderate to very severe COPD. This post hoc analysis investigated whether T/O is more effective than T at delaying clinically significant events in patients with GOLD stage B COPD. Methods A total of 5162 patients were randomised to O 5 µg, T 2.5 µg, T 5 µg, T/O 2.5/5 µg or T/O 5/5 µg (delivered via Respimat ® inhaler) in two 52-week, parallel-group, double-blind studies (NC…

Pulmonary and Respiratory Medicine030213 general clinical medicineCOPDmedicine.medical_specialtyRespimatExacerbationbusiness.industryInhalerOlodaterolmedicine.diseaseGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisInternal medicinePost-hoc analysismedicineIn patientRespiratory systembusinessThorax
researchProduct

Benefits of Tiotropium + Olodaterol Over Tiotropium at Delaying Clinically Significant Events in Patients with COPD Classified as GOLD B

2017

Pulmonary and Respiratory Medicine030213 general clinical medicineCOPDmedicine.medical_specialtybusiness.industryTiotropium-olodaterolmedicine.disease03 medical and health sciences0302 clinical medicine030228 respiratory systemInternal medicinemedicineIn patientbusinessPneumologie
researchProduct

DOES LEPTIN PLAY A CYTOKINE-LIKE ROLE WITHIN THE AIRWAYS OF COPD PATIENTS?

2005

The leptin-leptin receptor system might be up-regulated in the airways of chronic obstructive pulmonary disease (COPD). In bronchial biopsies obtained from normal subjects and smokers, with and without COPD, the present study examined leptin and leptin-receptor expression and their co-localisation in airway and inflammatory cells. Combining immunohistochemistry with terminal deoxynucleotidyl transferase dUTP nick end-labelling techniques, apoptosis in airway and inflammatory cells and in leptin and leptin-receptor expressing cells was investigated. In the epithelial cells both leptin and leptin-receptor expression was higher in normal subjects than in smokers and COPD subjects. By contrast,…

Pulmonary and Respiratory MedicineAdultLeptinMalemedicine.medical_specialtyCopd patientsmedicine.medical_treatmentT-LymphocytesApoptosisBronchiReceptors Cell SurfaceRespiratory MucosaPulmonary Disease Chronic ObstructiveInternal medicineBiopsyMedicineHumansAgedCOPDmedicine.diagnostic_testbusiness.industryLeptindigestive oral and skin physiologyRespiratory diseaseSmokingrespiratory systemMiddle Agedmedicine.diseaseObstructive lung diseaserespiratory tract diseasesRespiratory Function TestsEndocrinologyCytokineTerminal deoxynucleotidyl transferaseCase-Control StudiesImmunologyPhysical therapyReceptors LeptinFemalebusinesshormones hormone substitutes and hormone antagonistsCD8
researchProduct

Effects of cigarette smoke on methacholine- and AMP-induced air trapping in asthmatics.

2014

Abstract Objective: No information is available on the effect of cigarette smoke on bronchoconstrictor-induced air trapping in asthma. The aim of this study was to evaluate the additional influence of smoking on methacholine- and adenosine 5'-monophosphate (AMP)-induced air trapping in subjects with asthma.Airway responsiveness to methacholine and AMP, bronchial (J'awNO) and alveolar (CANO) nitric oxide (NO) and exhaled breath condensate pH were measured in 68 adults (23 current smokers with asthma, 23 non-smokers with asthma and 22 current or former smokers with chronic obstructive pulmonary disease; COPD). The degree of air trapping induced by each bronchoconstrictor agent was expressed b…

Pulmonary and Respiratory MedicineAdultMaleVital capacityVital CapacityAir trappingNitric OxideBronchoconstrictor AgentsFEV1/FVC ratioPulmonary Disease Chronic Obstructiveimmune system diseasesSmokeTobaccomedicineImmunology and AllergyHumansExhaled breath condensateMethacholine ChlorideAsthmaCOPDbusiness.industrySmokingrespiratory systemMiddle Agedmedicine.diseaseAdenosine MonophosphateAsthmarespiratory tract diseasesBreath TestsAnesthesiaPediatrics Perinatology and Child HealthExhaled nitric oxideMethacholineFemalemedicine.symptombusinessmedicine.drugThe Journal of asthma : official journal of the Association for the Care of Asthma
researchProduct

Impact of chronic obstructive pulmonary disease on the outcomes of patients with peripheral artery disease.

2019

Peripheral artery disease (PAD) and chronic obstructive pulmonary disease (COPD) are both related with high in-hospital mortality. We aimed to investigate the impact of COPD on the in-hospital outcomes in PAD.PAD patients were selected based on ICD-code I70.2 of the German nationwide database, stratified for COPD and compared regarding adverse in-hospital outcomes.Between 01/2005-12/2015, 5,611,827 inpatients (64.8% males) were diagnosed with PAD; of those, 13.6% were coded additionally with COPD. Overall, 277,894 PAD patients (5.0%) died during in-hospital course. Prevalence of cardiovascular diseases as well as cancer (12.1% vs. 7.0%, P  0.001) was higher in PAD patients with COPD compare…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyArterial diseasemedicine.medical_treatmentMyocardial InfarctionPulmonary diseaseDiseaseIndependent predictorAmputation Surgical03 medical and health sciencesPeripheral Arterial DiseasePulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsInternal medicineNeoplasmsmedicinePrevalenceHumans030212 general & internal medicineHospital MortalityAgedAged 80 and overCOPDbusiness.industryNationwide databaseCancerMiddle Agedmedicine.diseaserespiratory tract diseases030228 respiratory systemAmputationCardiovascular DiseasesFemalebusinessPulmonary EmbolismRespiratory medicine
researchProduct

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.

2008

This dose-ranging study assessed the bronchodilator efficacy and tolerability of indacaterol, a novel once-daily inhaled beta2-agonist, in subjects clinically diagnosed with COPD. Comparative data with tiotropium were collected. In the double-blind, core period of the study, 635 subjects with COPD (prebronchodilator FEV(1)40% of predicted and > or =1.0L; FEV1/FVC <70%) were randomized to receive indacaterol 50, 100, 200 or 400microg or placebo via multi-dose dry powder inhaler, or indacaterol 400microg via single-dose dry powder inhaler, once daily for 7 days. After completing double-blind treatment and washout, a subset of subjects from each treatment group entered an open-label extension …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyEfficacymedicine.drug_classScopolamine DerivativesQuinolonesFEV1/FVC ratioPulmonary Disease Chronic ObstructiveDouble-Blind MethodBronchodilatorForced Expiratory VolumeAdministration InhalationCOPDMedicineHumansTiotropium BromideIndacaterolAgedCOPDDose-Response Relationship Drugbusiness.industryTiotropiumTiotropium bromideMiddle AgedDose-ranging studymedicine.diseaseDry-powder inhalerrespiratory tract diseasesSurgeryBronchodilator AgentsTreatment OutcomeTolerabilityDoseAnesthesiaIndansIndacaterolFemaleSafetybusinessmedicine.drugRespiratory medicine
researchProduct

Airway distensibility by HRCT in asthmatics and COPD with comparable airway obstruction.

2013

Introduction: Decreased airway distensibility (AD) in response to deep inspirations, as assessed by HRCT, has been associated with the severity of asthma and COPD. Aims: The current study was designed to compare the magnitude of AD by HRCT in individuals with asthma and COPD with comparable degrees of bronchial obstruction, and to explore factors that may influence it. Results: We enrolled a total of 12 asthmatics (M/F:7/5) and 8 COPD (7/1) with comparable degree of bronchial obstruction (FEV1% predicted mean±SEM: 69.1 ± 5.2% and 61.2 ± 5.0%, respectively; p = 0.31). Each subject underwent chest HRCT at FRC and at TLC. A total of 701 airways (range 20 to 38 airway per subject; 2.0 to 23.1 m…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyVital CapacityLung Volume MeasurementSettore MED/10 - Malattie Dell'Apparato RespiratorioImagingDeep inspirationPulmonary Disease Chronic ObstructiveInternal medicineForced Expiratory VolumeMultidetector Computed TomographyMedicineHumansLung volumesBronchial obstructionLungAsthmaAgedCOPDbusiness.industryrespiratory systemAirway obstructionMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesLung volumeAirway distensibility Asthma COPDSpirometryCardiologyFemaleRadiologyAirwaybusinessLung Volume MeasurementsHumanCOPD
researchProduct